FDA Nonprescription Office Adding Staff To Focus On Monograph Work
This article was originally published in The Tan Sheet
Executive Summary
FDA's Division of Nonprescription Regulation Development will hire additional staff to accelerate monograph work and enhance the office's internal expertise
You may also be interested in...
FDA Expands Acetaminophen, NSAID Labeling Beyond Tentative Final Rule
FDA's final rule for OTC products containing acetaminophen or nonsteroidal anti-inflammatory drugs requires warnings and revisions that go beyond changes the agency proposed in a 2006 tentative final rule
Acetaminophen Risk Management On Tap For Joint Advisory Panel
FDA is looking for risk-management solutions to liver problems linked to the misuse of acetaminophen in OTC and prescription products, and will convene a joint advisory panel to discuss potential steps to take
FDA Amends OTC Oral Sodium Phosphate Labeling, Warns Of Risks
FDA recommends consumers not use OTC oral sodium phosphate for bowel cleansing and says it will amend labeling for the products because of a risk of serious kidney injuries